Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Alfonso Cordero-BarrealIDIS (Instituto de Investigación Sanitaria de Santiago), C027 NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Trav Choupana s/n, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-0827-8977
Djedjiga Ait EldjoudiIDIS (Instituto de Investigación Sanitaria de Santiago), C027 NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Trav Choupana s/n, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-0638-4223
Mariam FarragIDIS (Instituto de Investigación Sanitaria de Santiago), C027 NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Trav Choupana s/n, 15706 Santiago de Compostela, Spain.ORCID 0000-0001-6403-5999
Laura González-BlancoIDIS (Instituto de Investigación Sanitaria de Santiago), C027 NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Trav Choupana s/n, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-2257-9012
Maximo Alberto Diez-UlloaDivision of Orthopaedics and Traumatological Surgery, Santiago University Clinical Hospital, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-0476-1507
Miguel Ángel González-GayDivision of Rheumatology, Fundación Jiménez-Diaz Instituto de Investigación Sanitaria, 28006 Madrid, Spain.ORCID 0000-0002-7924-7406
Raquel LargoDivision of Rheumatology, Fundación Jiménez-Diaz Instituto de Investigación Sanitaria, 28006 Madrid, Spain.ORCID 0000-0001-6525-2944
Francisca LagoSERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), Molecular and Cellular Cardiology Lab, Research Laboratory 7, Santiago University Clinical Hospital, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-4593-8399
Yousof FarragIDIS (Instituto de Investigación Sanitaria de Santiago), C027 NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Trav Choupana s/n, 15706 Santiago de Compostela, Spain.ORCID 0000-0003-1715-8157
Jesus PinoIDIS (Instituto de Investigación Sanitaria de Santiago), C027 NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Trav Choupana s/n, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-1847-1199
Oreste GualilloIDIS (Instituto de Investigación Sanitaria de Santiago), C027 NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Trav Choupana s/n, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-7154-1328
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Lumbar spinal stenosis (LSS) is caused by multiple degenerative changes including the hypertrophy of the ligamentum flavum (LFH). Inflammation and fibrosis contribute to LFH and glucocorticoid drugs (GCDs) are generally used to manage LSS symptoms. However, a thorough understanding of the molecular mechanisms exerted by GCD in ligamentum flavum (LF) cells remains incomplete. Primary human LF cells were isolated from surgical specimens and stimulated with pro-inflammatory agents (IL-1α, IL-1β, LPS) or the profibrotic cytokine TGFβ1, in the presence or absence of dexamethasone. Gene and protein expression levels of inflammatory, fibrotic, and ossification-related markers were analysed using RT-qPCR and Western blotting. Dexamethasone significantly suppressed the expression of key pro-inflammatory, fibrotic, and ossification markers (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Novel Molecular Insights into the Anti-Inflammatory and Antifibrotic Effects of Dexamethasone on Human Ligamentum Flavum-Derived Cells. · full record | OpenQuestion